The development of medications for alcohol-use disorders targeting the GABAB receptor system

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 2, 2012, Pages 113-128

  Agabio, Roberta ^a   Maccioni, Paola ^b   Carai, Mauro A M ^b   Gessa, Gian Luigi ^a,b   Froestl, Wolfgang ^c   Colombo, Giancarlo ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR Neuroscience Institute   (Italy)

^c AC IMMUNE SA   (Switzerland)

Author keywords

Alcohol use disorders; Animal models of alcohol dependence; Baclofen; GS39783; Positive allosteric modulators

Indexed keywords

2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR POSITIVE ALLOSTERIC MODULATOR; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 5,7 DI TERT BUTYL 3 HYDROXY 3 TRIFLUOROMETHYL 3H BENZOFURAN 2 ONE; BACLOFEN; BENZODIAZEPINE; DIAZEPAM; DOPAMINE; ELECTROLYTE; N (BICYCLO[2.2.1]HEPT 2 YL) 2 METHYL 5 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINAMINE; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; NVP BHF 177; SODIUM CHLORIDE; THIAMINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL SELF ADMINISTRATION; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; ASSOCIATION; CLINICAL EVALUATION; CLINICAL INSTITUTE WITHDRAWAL ASSESSMENT FOR ALCOHOL REVISED SCALE; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DOPAMINE RELEASE; DOSE RESPONSE; DRINKING BEHAVIOR; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SPECIFICITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EUPHORIA; EXPERIMENTAL TEST; FATIGUE; FLUID INTAKE; HUMAN; HYPOTENSION; INHIBITION KINETICS; INSOMNIA; ITALY; LIVER DISEASE; LIVER METABOLISM; LOCOMOTION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MENTAL DISEASE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOTIVATION; NAUSEA; NONHUMAN; NUCLEUS ACCUMBENS; PATENT; PLACE PREFERENCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFORCEMENT; REWARD; SEDATION; SIDE EFFECT; SOMNOLENCE; STIMULUS RESPONSE; TREATMENT OUTCOME; UNITED STATES; VENTRAL TEGMENTUM; VERTIGO; WEAKNESS;

EID: 84861729993     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912800673137     Document Type: Article

References (138)

1. Grant KA, Lovinger DM. Cellular and behavioral neurobiology of alcohol: receptor-mediated neuronal processes. Clin Neurosci 1995; 3: 155-64.
2. Koob GF, Le Moal M. Alcohol. In: Koob GF, Le Moal M, Eds. Neurobiology of Addiction. Oxford: Academic Press 2006; 173-241.
3. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 2009; 89: 649-705.
4. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev 2004; 84: 835-67.
5. B receptor. Biochem Pharmacol 2004; 68: 1527-36.
6. B receptors: structure and function. In: Tepper JM, Abercrombie ED, Bolam JP, Eds. GABA and the Basal Ganglia, Progress in Brain Research, Vol. 160. Amsterdam: Elsevier 2007: 43-57.
7. B receptor ligands. Adv Pharmacol 2010; 58: 19-62.
8. B receptor: a site of therapeutic benefit. Curr Opin Pharmacol 2006; 6: 37-43.
9. B receptors: structure and function. Pharmacol Rev 2002; 54: 247-64.
10. B receptor. J Biol Chem 2004; 279: 29085-91.
11. B1 subunit. Mol Pharmacol 2006; 70: 2027-36.
12. B receptors. In: Bowery NG, Ed. Allosteric receptor modulation in drug targeting. New York: Informa Healthcare (Taylor & Francis), 2006; 235-58.
13. B receptors: mechanism of action and therapeutic perspective. Curr Neuropharmacol 2007; 5: 195-201.
14. Schwartz TW, Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 2007; 28: 366-73.
15. B receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001; 60: 963-71.
16. Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, et al. N, N'-Dicyclopentyl-2-methylsulfanyl-5-nitropyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 2003; 307: 322-30.
17. B receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 2005; 48: 343-53.
18. Langmead CJ, Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol Sci 2006; 27: 475-81.
19. B receptor desensitization. Neuropharmacol 2008; 55: 1293-99.
20. B receptor-positive modulator GS39783 (N, N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 2004; 310: 952-63.
21. B receptors in the modulation of anxiety-and antidepressantlike behavior. Neuropsychopharmacology 2004; 29:1050-62.
22. B receptor ligands in animal tests of depression and anxiety. Pharmacol Rep 2007; 59: 645-55.
23. B receptor positive modulator CGP7930 in rodents. Neuropharmacology 2008; 54: 854-62.
24. B receptors. Br J Pharmacol 2008; 154, 797-811.
25. Colombo G, Lobina C, Carai MAM, Gessa GL. Phenotypic characterization of genetically selected Sardinian alcohol-preferring (sP) and-non preferring (sNP) rats. Addict Biol 2006; 11: 324-38.
26. Quintanilla ME, Israel Y, Sapag A, Tampier L. The UChA and UChB rat lines: metabolic and genetic differences influencing ethanol intake. Addict Biol 2006; 11: 310-23.
27. B receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol 2002; 37: 499-503.
28. Smith BR, Robidoux J, Amit Z. GABAergic involvement in the acquisition of voluntary ethanol intake in laboratory rats. Alcohol Alcohol 1992; 27: 227-31.
29. Quintanilla ME, Perez E, Tampier L. Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats. Addict Biol 2008; 13: 326-36.
30. Colombo G, Agabio R, Carai MAM, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I-Preclinical evidence. Alcohol Clin Exp Res 2000; 24: 58-66.
31. Daoust M, Saligaut C, Lhuintre JP, Moore N, Flipo JL, Boismare F. GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol 1987; 4: 469-72.
32. B agonist baclofen on the temporal and structural characteristics of ethanol intake. Alcohol 1999; 17: 231-40.
33. Stromberg MF. The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol Biochem Behav 2004; 78: 743-50.
34. Spanagel R. Animal models of behaviors: alcohol addiction. In: Koob GF, Le Moal M, Thompson RF, Eds. Encyclopedia of Behavioral Neuroscience, Vol. 1. Oxford: Academic Press 2010; 65-70.
35. Colombo G, Serra S, Brunetti G, Vacca G, Carai MAM, Gessa GL. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003; 70: 105-8.
36. Colombo G, Serra S, Vacca G, Carai MAM, Gessa GL. Baclofeninduced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. Eur J Pharmacol 2006; 550: 123-6.
37. Moore EM, Boehm SL. Site-specific microinjection of baclofen into the anterior ventral tegmental area reduces binge-like ethanol intake in male C57BL/6J mice. Behav Neurosci 2009; 123: 555-63.
38. Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav 2005; 84: 53-63.
39. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF. Animal models of drug craving. Psychopharmacology 1993; 112: 163-82.
40. Anstrom KK, Cromwell HC, Markowski T, Woodward DJ. Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res 2003; 27: 900-8.
41. Janak PH, Gill TM. Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose. Alcohol 2003; 30: 1-7.
42. B receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology 2004; 174: 358-66.
43. Maccioni P, Serra S, Vacca G, Orrù A, Pes D, Agabio R, et al. Baclofen-induced reduction of alcohol reinforcement in alcoholpreferring rats. Alcohol 2005; 36: 161-8.
44. B receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcoholpreferring rats. Neuropharmacology 2006; 50: 632-9.
45. Walker BM, Koob GF. The-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res 2007; 31: 11-8.
46. Petry NM. Benzodiazepine-GABA modulation of concurrent ethanol and sucrose reinforcement in the rat. Exp Clin Psychopharmacol 1997; 5: 183-94.
47. B agonist baclofen in rats. Alcohol Clin Exp Res 2006; 30: 812-8.
48. B receptor direct agonist, baclofen. Alcohol Clin Exp Res 2008; 32: 1558-64.
49. Colombo G, Vacca G, Serra S, Brunetti G, Carai MAM, Gessa GL. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology 2003; 167: 221-4.
50. Leite-Morris KA, Czachowski CL. Intra-ventral tegmental area microinjections of a GABA receptor agonist dose-dependently attenuate ethanol seeking in rats. Alcohol Clin Exp Res 2006; 30: 182A.
51. Leite-Morris KA, Misch ES, Czachowski CL. Intra-VTA activation of GABA(B) receptors modulates accumbal dopamine during ethanol seeking behavior. Alcohol Clin Exp Res 2008; 32: 276A.
52. Maccioni P, Bienkowski P, Carai MAM, Gessa GL, Colombo G. Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2008; 95: 284-7.
53. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987; 94: 469-92.
54. Cott J, Carlsson A, Engel J, Lindqvist M. Suppression of ethanolinduced locomotor stimulation by GABA-like drugs. Naunyn-Schmiedeberg's Arch Pharmacol 1976; 295: 203-9.
55. B receptors in mediating the stimulatory effects of ethanol in mice. Psychopharmacology 1993; 111: 219-24.
56. Shen EH, Dorow J, Harland R, Burkhart-Kasch S, Phillips TJ. Seizure sensitivity and GABAergic modulation of ethanol sensitivity in selectively bred FAST and SLOW mouse lines. J Pharmacol Exp Ther 1998; 287: 606-15.
57. B agonists on sensitization to the locomotor stimulant effects of ethanol in DBA/2 J mice. Psychopharmacology 1999; 141: 197-205.
58. Chester JA, Cunningham CL. Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol Biochem Behav 1999; 63: 325-31.
59. B receptor modulation of ethanol-stimulated activity in mice. Neuroscience 2002; 115: 185-200.
60. Leite-Morris KA. The effects of ventral tegmental baclofen on ethanol-induced motor stimulation and sensitization in DBA/2 mice. Alcohol Clin Exp Res 2004; 28: 182A.
61. Arias C, Mlewski EC, Molina JC, Spear NE. Naloxone and baclofen attenuate ethanol's locomotor-activating effects in preweanling Sprague-Dawley rats. Behav Neurosi 2009; 123: 172-80.
62. B, receptor agonist. Alcohol Clin Exp Res 2009; 33: 108-20.
63. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.
64. Tzcshentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56: 613-72.
65. Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007; 12: 227-462.
66. Bechtholt AJ, Cunningham CL. Ethanol-induced conditioned place preference is expressed through a ventral tegmental area dependent mechanism. Behav Neurosci 2005; 119: 213-23.
67. File SE, Zharkovsky A, Gulati K. Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacol 1991; 30: 183-90.
68. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res 2007; 31: 582-95.
69. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002; 22: 3332-7.
70. B receptor site distribution in the rat central nervous system. Neurosci 1987; 20: 365-83.
71. Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 1993; 18: 75-113.
72. Yoshida M, Yokoo H, Tanaka T, Emoto H, Tanaka M. Opposite changes in the mesolimbic metabolism in the nerve terminal and cell body sites induced by locally infused in the rat. Brain Res 1994; 636: 111-4.
73. Westerink BHC, Kwint HF, deVries JB. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 1996; 16: 2605-11.
74. Grant KA. Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels. Behav Pharmacol 1994; 5: 383-404.
75. B receptor and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 1995; 46: 423-62.
76. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IVTR). Washington DC 2000.
77. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2007; 64: 830-42.
78. Saitz R. Unhealthy alcohol use. N Engl J Med 2005; 352: 596-607.
79. Cargiulo T. Understanding the health impact of alcohol dependence. Am J Health Syst Pharm 2007; 64: S5-11.
80. Schuckit MA. Alcohol-use disorders. Lancet 2009; 373: 492-501.
81. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 2006; 111: 855-76.
82. Jupp B, Lawrence AJ. New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther 2010; 125: 138-68.
83. Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II-Preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24: 67-71.
84. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37: 504-8.
85. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915-22.
86. Flannery BA, Garbutt JC, Cody MW, Renn W, Grace K, Osborne M, et al. Baclofen for alcohol dependence: a preliminary openlabel study. Alcohol Clin Exp Res 2004; 28: 1517-23.
87. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34: 1849-57.
88. Gerkin R, Curry SC, Vance MV, Sankowski PW, Meinhart RD. First-order elimination kinetics following baclofen overdose. Ann Emerg Med 1986; 15: 843-6.
89. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2005; 40: 147-50.
90. Ameisen O. The End of My Addiction. How One Man Cured Himself of Alcoholism. Piatkus Press: London 2009.
91. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJa, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend 1993; 33: 157-63.
92. Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol 2007; 42: 158-60.
93. Agabio R, Marras P, Addolorato G, Carpiniello B, Gessa GL. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J Clin Psychopharmacol 2007; 27: 319-20.
94. Hall W, Zador D. The alcohol withdrawal syndrome. Lancet 1997; 349: 1897-900.
95. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. J Am Med Assoc 1997; 278: 144-51.
96. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 2002; 112: 226-9.
97. Addolorato G, Leggio L, Abenavoli L, DeLorenzi G, Parente A, Caputo F, et al. Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin Neuropharmacol 2003; 26: 258-62.
98. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119: 276. e13-8.
99. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Safety 2004; 27: 799-818.
100. Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 2009; 33: 19-30.
101. Robson, R.D., Saelens, J.K. 4-Amino-3-p-halophenyl butyric acids and their derivatives used in the control of narcotic abuse. US4126684 (1978).
102. B receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinencedependent patients. WO01008675 (2001).
103. Fattore L, Cossu G, Martellotta MC, Fratta W. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol 2002; 37: 495-8.
104. Gessa, G.L., Colombo, G., Addolorato, G. The use of baclofen in the treatment of alcoholism. WO01026638 (2001).
105. Goeders, N.E. Compositions and methods for the treatment of addiction and other neuropsychiatric disorders. WO2007056618 (2007).
106. Dean, R.L., Deaver, D., Ehrich, E. Methods and compositions for the treatment of brain reward system disorders by combination therapy. WO2007056300 (2007).
107. Ehrich, E. Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers. WO2007089934 (2007).
108. Colombo G, Serra S, Vacca G, Carai MAM, Gessa GL. Effect of the combination of naltrexone and baclofen on acquisition of alcohol drinking behavior in alcohol-preferring rats. Drug Alcohol Depend 2005; 77: 87-91.
109. Kidney, D.J., Cundy, K.C., Sastry, S., Leung, M. Sustained release oral dosage forms of a prodrug of R-baclofen and methods of treatment. WO2008086492 (2008).
110. Sastry, S., Cundy, K., Leung, M. Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treatment. WO2009096985 (2009).
111. Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009; 330: 911-21.
112. B receptors. Bioorg Med Chem Lett 2007; 17: 6206-11.
113. B receptor, CGP7930 and GS39783, on alcohol intake in alcoholpreferring rats. Eur J Pharmacol 2005; 525: 105-11.
114. B receptor, GS39783, on alcohol self-administration in alcohol-preferring rats. Psychopharmacology 2007; 193: 171-8.
115. B receptor, BHF177, in alcohol-preferring rats. Alcohol Clin Exp Res 2009; 33: 1749-56.
116. B receptor, rac-BHFF, suppresses alcohol self-administration. Drug Alcohol Depend 2010; 109: 96-103.
117. B receptor, GS39783, of alcohol self-administration in Sardinian alcohol-preferring rats exposed to the "sipper" procedure. Front Psych 2010; 1: 20. doi:10.3389/fpsyt.2010.00020.
118. B mediated nervous system disorders. WO2006136442 (2006).
119. B receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther 2008; 326: 306-14.
120. th Society for Neuroscience Annual Meeting 2008b; November 19 (Abs 824.5/C45).
121. B receptor modulators. WO2008056257 (2008).
122. Malherbe, P., Masciadri, R., Prinssen, E., Spooren, W., Thomas, A.W. 4-(Sulfanyl-pyrimidine-4-yl-methyl)-morpholine derivatives and related compounds as GABA receptor ligands for the treatment of anxiety, depression and epilepsy. WO2005094828 (2005).
123. B receptors. WO2006048146 (2006).
124. B allosteric enhancers. WO2006063732 (2006).
125. B enhancers. WO2006128802 (2006).
126. B receptor. WO2007014843 (2007).
127. B positive allosteric modulator (R, S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3 H-benzofuran-2-one. Synth Commun 2008; 38: 3398-405.
128. Bauer, U., Brailsford, W., Chhajlani, V., Egner, B., Fjellström, O., Gustafsson, L. et al. Imidazole variants as modulators of GABA receptor for the treatment of GI disorders. WO2006001750 (2006).
129. Bauer, U. Pyrazoles for the treatment of GERD and IBS. WO2007073297 (2007).
130. B modulators. WO2007073296 (2007).
131. Bauer, U., Brailsford, W., Gustafsson, L., Saxin, M., Svensson, T. Imidazole derivatives for the treatment of gastrointestinal disorders. WO2007073298 (2007).
132. B receptor modulators. WO2007073299 (2007).
133. B receptor modulators. WO2007073300 (2007).
134. Bauer, U., Brailsford, W., Cheng, L., Jonforsen, M., Raubacher, F., Schell, P. Imidazole derivatives as modulators of the GABA receptor for the treatment of gastrointestinal disorders. WO2008130313 (2008).
135. B receptor modulator effect. WO2008130314 (2008).
136. B receptor. WO2009041904 (2009).
137. B receptors. WO2009041905 (2009).
138. Miller G. Tackling alcoholism with drugs. Science 2008; 320: 168-70.